Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study.
BACKGROUND
Once-daily tenofovir/emtricitabine-based pre-exposure prophylaxis (PrEP) can reduce HIV acquisition in men who have sex with men (MSM), by 44% in the iPrEx trial, and reaching up to 99% with high adherence. We examined the potential population-level impact and cost-effectiveness of different PrEP implementation strategies.


METHODS
We developed a dynamic, stochastic compartmental model of HIV transmission among the estimated 57,400 MSM in Toronto, Canada. Parameterization was performed using local epidemiologic data. Strategies examined included (1) uniform PrEP delivery versus targeting the highest risk decile of MSM (with varying coverage proportions); (2) increasing PrEP efficacy as a surrogate of adherence (44% to 99%); and (3) varying HIV test frequency (once monthly to once yearly). Outcomes included HIV infections averted and the incremental cost ($CAD) per incremental quality-adjusted-life-year (QALY) gained over 20 years.


RESULTS
Use of PrEP among all HIV-uninfected MSM at 25, 50, 75 and 100% coverage prevented 1970, 3427, 4317, and 4581 infections, respectively, with cost/QALY increasing from $500,000 to $800,000 CAD. Targeted PrEP for the highest risk MSM at 25, 50, 75 and 100% coverage prevented 1166, 2154, 2816, and 3012 infections, respectively, with cost/QALY ranging from $35,000 to $70,000 CAD. Maximizing PrEP efficacy, in a scenario of 25% coverage of high-risk MSM with PrEP, prevented 1540 infections with a cost/QALY of $15,000 CAD. HIV testing alone (Q3 months) averted 898 of infections with a cost savings of $4,000 CAD per QALY.


CONCLUSIONS
The optimal implementation strategy for PrEP over the next 20 years at this urban centre is to target high-risk MSM and to maximize efficacy by supporting PrEP adherence. A large health benefit of PrEP implementation could come from engaging undiagnosed HIV-infected individuals into care.
Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Derek R
DR
MacFadden
Division of Infectious Diseases, Department of Medicine, St. Michael's Hospital, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada.
Darrell H
DH
Tan
Division of Infectious Diseases, Department of Medicine, St. Michael's Hospital, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada.|Department of Infectious Disease Epidemiology, Imperial College, London, United Kingdom; sharmisthak@gmail.com.
Sharmistha
S
Mishra
HIV; PrEP; cost-effectiveness; dynamic model; prevention; prophylaxis
Clin Infect Dis. 2014 May;58(9):1297-307
24457345
N Engl J Med. 2010 Dec 30;363(27):2587-99
21091279
Sci Transl Med. 2012 Sep 12;4(151):151ra125
22972843
Clin Infect Dis. 2011 Dec;53(12):1265-70
21976467
Sex Transm Dis. 2011 May;38(5):419-28
21183863
Clin Infect Dis. 2011 Oct;53(8):817-25
21921225
AIDS Care. 2011 Jul;23(7):892-900
21424942
Natl Vital Stat Rep. 2014 Nov;63(7):1-63
25383611
Cochrane Database Syst Rev. 2002;(1):CD003255
11869658
BMC Public Health. 2013 Jun 24;13:606
23800206
AIDS. 2008 Sep 12;22(14):1829-39
18753932
Ann Intern Med. 2012 Apr 17;156(8):541-50
22508731
J Infect Dis. 2005 May 1;191(9):1403-9
15809897
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e51-2
21921730
Clin Infect Dis. 2007 Apr 15;44(8):1115-22
17366461
HIV Med. 2008 Oct;9(9):721-30
18643856
Clin Infect Dis. 2014 Apr;58(7):1027-34
24385445
AIDS Behav. 2014 Apr;18 Suppl 3:S237-47
23955658
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):446-53
16010168
Clin Infect Dis. 2009 Mar 15;48(6):806-15
19193111
AIDS Patient Care STDS. 2006 Apr;20(4):245-57
16623623
CMAJ. 1993 Mar 15;148(6):927-9
8448707
AIDS. 2003 May 2;17(7):1029-38
12700453
N Engl J Med. 2005 Feb 10;352(6):570-85
15703422
Lancet. 2016 Jan 2;387(10013):53-60
26364263
Can Commun Dis Rep. 2015 Dec 03;41(12):292-303
29769924
N Engl J Med. 2011 Aug 11;365(6):493-505
21767103
Int J Health Geogr. 2011 Apr 17;10:28
21496324
Lancet. 2013 Jun 15;381(9883):2083-90
23769234
Lancet Infect Dis. 2014 Sep;14(9):820-9
25065857
HIV Med. 2013 Oct;14(9):581-2
24033869
N Engl J Med. 2015 Dec 3;373(23):2237-46
26624850
AIDS. 2013 Nov 28;27(18):2943-51
23939237
PLoS Med. 2014 Mar 04;11(3):e1001613
24595035
PLoS Med. 2012;9(10):e1001323
23055836
N Engl J Med. 2012 Aug 2;367(5):399-410
22784037
AIDS Educ Prev. 2011 Dec;23(6):577-94
22201240